Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 American Society of Clinical Oncology Annual Meeting

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NATICK, Mass., May 15, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that clinical data for its lead drug candidate, KPT-330, in patients with advanced solid tumors will be presented in the Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics oral abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31st – June 4th, 2013 in Chicago, Illinois. KPT-330 is an oral, small molecule Selective Inhibitor of Nuclear Export (SINE) that induces cell death selectively in cancer cells through forced nuclear retention and activation of tumor suppressor proteins by blocking Exportin 1 (XPO1).

Help employers find you! Check out all the jobs and post your resume.

Back to news